Using the abYsis database for drug discovery
Posted 30th April 2021 by Nicholas Noakes
Professor Andrew Martin, UCL, speaking at the 4th Global Pharma R&D AI, Data Science and Informatics Summit, described using the abYsis database and workbench for drug discovery. He showed how it is possible to explore an annotate antibody sequence and structure, including comparisons with observed residue distributions. The database can also aid with humanization by making sequences more human and library design.
AI to leverage data and close the loop between patient data and R&D
Posted 15th October 2020 by Nicholas Noakes
Ahead of the Global Pharma R&D AI, Data Science and Informatics Summit we sat down with Claire Biot to talk about her work to provide life science companies & professionals with a scientific and business platform to imagine sustainable innovations, capable of improving patient & physician experience in the age of precision medicine.
Reshaping drug discovery with deep learning and polypharmacology
Posted 23rd October 2019 by Joshua Sewell
Cyclica is a Toronto-based biotech that leverages artificial intelligence and computational biophysics to reshape the drug discovery process. We spoke to their Chief Scientific Officer Andreas Windemuth.
Will the intersection of blockchain and AI inspire the Pharma R&D Renaissance?
Posted 30th September 2019 by Joshua Sewell
Global Engage spoke to Scott Kahn ahead of the 3rdGlobal Pharma R&D Informatics and AI Congress. Scott is the CIO of Luna PBC, the entity that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
This is the second half of that conversation, where Scott discusses the challenges of distributive ledger technologies such as Blockchain, and their intersection with AI for Pharma R&D.
How to revolutionise clinical trials: engaging with participants as partners
Posted 23rd September 2019 by Joshua Sewell
Ahead of the 3rd Global Pharma R&D Informatics and AI Congress, Global Engage spoke to Scott Kahn, CIO of LunaPBC. LunaPBC is the company that manages LunaDNA: a community-owned data-sharing resource. Their conversation was recorded as a podcast, which can be found here.
In the first half of the conversation, Scott discusses the benefits of distributive ledger technologies such as Blockchain for Pharma R&D.
The future of Pharma: harnessing AI to decentralise data
Posted 9th September 2019 by Joshua Sewell
As Chief Data Officer for the OSTHUS Group, Eric Little co-founded LeapAnalysis, a new approach to AI, data integration and analytics.
LeapAnalysis is the first fully federated and virtualised search and analytics engine that runs on semantic metadata. It allows users to combine semantic models (ontologies) with machine learning algorithms to provide customers with unparalleled flexibility in utilizing their data.
The benefits of network-driven drug discovery
Posted 19th August 2019 by Jane Williams
e-Therapeutics, an Oxford-based company, is using its network-driven drug discovery (NDD) technology to embrace the inherent complexity of biology, providing a novel and productive method for the discovery of new medicines.
Jonny Wray is the head of Discovery Informatics at e-Therapeutics. Trained as a computational neuroscientist, he is responsible for building the NDD technology. We spoke to him ahead of his presentation at the Global Pharma R&D Informatics & AI Congress.
Going back to biology and the hype of AI in pharma
Posted 2nd August 2019 by Jane Williams
With a background in pharmacology, toxicology, molecular cell biology and genetics, Rangaprasad Sarangarajan joined BERG Health in 2010 as head of R&D.
In the initial years of the company, he aided in the conception, design, and implementation of the paradigm of looking at human biology, use of technology to generate molecular signatures, and the use of artificial intelligence-based analytics for understanding the complexity of biology, identifying of targets, and developing of drugs, and its utility in clinical development.